Literature DB >> 24391408

Human papilloma virus (HPV) vaccination in childhood: challenges and perspectives.

I Mammas1, F Maher2, M Theodoridou3, D Spandidos4.   

Abstract

Vaccination against human papilloma virus (HPV) in childhood is a significant step forward in the reduction of HPV associated morbidity and mortality and a considerable scientific achievement. However, many challenges remain to be overcome if an effective HPV vaccine programme is to be successfully introduced worldwide. The aim of this review is to identify and summarize the new issues concerning HPV vaccination that have emerged since its introduction into clinical practice in school-aged girls. According to the literature, the overall impact of HPV vaccination on cervical cancer is unlikely to be apparent for the next decade. Cost-effectiveness is of particular importance, particularly in developing countries. Determining the age at which the vaccine should be administered, whether to include boys in addition to girls, the costs and the implications for cervical screening are issues that need to be addressed by conducting further research.

Entities:  

Keywords:  children; human papilloma virus; review; school-aged girls; vaccination

Year:  2011        PMID: 24391408      PMCID: PMC3876842     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  42 in total

1.  HPV/cervical cancer vaccination: parental preferences on age, place and information needs.

Authors:  Sally B Rose; Beverley A Lawton; Tolotea Lanumata; Merilyn Hibma; Michael G Baker
Journal:  J Prim Health Care       Date:  2010-09-01

2.  Human papillomavirus (HPV) vaccine uptake and completion at an urban hospital.

Authors:  Nicholas H Schluterman; Mishka Terplan; Alison D Lydecker; J Kathleen Tracy
Journal:  Vaccine       Date:  2011-04-06       Impact factor: 3.641

3.  Persistent high-risk human papillomavirus (HPV) infections as surrogate endpoints of progressive cervical disease. Potential new endpoint for efficacy studies with new-generation (non-HPV 16/18) prophylactic HPV vaccines.

Authors:  K Syrjänen
Journal:  Eur J Gynaecol Oncol       Date:  2011       Impact factor: 0.196

4.  Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.

Authors:  Doris M Rivera Medina; Alejandra Valencia; Alet de Velasquez; Li-Min Huang; Roman Prymula; Jose García-Sicilia; Lars Rombo; Marie Pierre P David; Dominique Descamps; Karin Hardt; Gary Dubin
Journal:  J Adolesc Health       Date:  2010-05       Impact factor: 5.012

Review 5.  Prevention strategies against human papillomavirus in males.

Authors:  Suzanne M Garland
Journal:  Gynecol Oncol       Date:  2010-02-16       Impact factor: 5.482

6.  Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy.

Authors:  S Y Chan; H Delius; A L Halpern; H U Bernard
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

7.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

8.  Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Authors:  Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr
Journal:  Pediatr Infect Dis J       Date:  2007-03       Impact factor: 2.129

Review 9.  Human papillomavirus vaccines and the potential for cross-protection between related HPV types.

Authors:  Kevin A Ault
Journal:  Gynecol Oncol       Date:  2007-11       Impact factor: 5.482

10.  Explaining variation in the uptake of HPV vaccination in England.

Authors:  Varun M Kumar; David K Whynes
Journal:  BMC Public Health       Date:  2011-03-22       Impact factor: 3.295

View more
  2 in total

Review 1.  Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses.

Authors:  Mireia Diaz; Silvia de Sanjosé; F Xavier Bosch; Laia Bruni
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-26

2.  The paediatric story of human papillomavirus (Review).

Authors:  Ioannis N Mammas; George Sourvinos; Demetrios A Spandidos
Journal:  Oncol Lett       Date:  2014-06-04       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.